Study guide

5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy

Key Takeaways Explain This Topic AI

For mild-to-moderate spontaneous ICH with SBP 150–220 mmHg, the 2022 AHA/ASA guideline says lowering SBP to a target of 140 mmHg (keeping it in the 130–150 mmHg range) is reasonable, and lowering SBP below 130 mmHg is potentially harmful.

In aneurysmal subarachnoid hemorrhage (aSAH), blood pressure should be maintained at SBP <160 mmHg prior to surgical clipping or endovascular coiling to prevent fatal rebleeding.

Oral nimodipine (60 mg PO/NG every 4 hours for 21 days) is mandatory in aSAH to prevent delayed ischemic neurological deficits from microvascular spasm and spreading depolarization; intravenous administration is strictly prohibited due to fatal cardiovascular collapse.

Emergent osmotherapy for intracranial hypertension and impending herniation utilizes 3% hypertonic saline (250 to 500 mL IV bolus, target serum sodium 145 to 155 mEq/L, osmolarity <320 mOsm/L) or 23.4% NaCl (30 mL IV via CVC); 20% mannitol (0.5 to 1 g/kg IV through an in-line filter) is an alternative but induces osmotic diuresis and is contraindicated in hypotension (SBP <90 mmHg).

Last updated: October 2026

5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around neurocritical care and emergency pharmacotherapy principles.

Intracranial hemorrhage encompasses spontaneous intracerebral hemorrhage (sICH) and aneurysmal subarachnoid hemorrhage (aSAH), both carrying high morbidity and mortality. Unlike acute ischemic stroke where the core goal is reperfusion, the emergency pharmacotherapy of acute intracranial hemorrhage focuses on immediate hemostasis, preventing hematoma expansion, averting secondary rebleeding, preserving cerebral perfusion pressure, and rapidly mitigating elevated intracranial pressure (ICP).

Spontaneous Intracerebral Hemorrhage (sICH): Hemodynamic Control

Spontaneous intracerebral hemorrhage is most frequently caused by rupture of small penetrating arterioles damaged by chronic hypertension (lipohyalinosis) or cerebral amyloid angiopathy (CAA). Approximately 30% to 38% of patients experience significant hematoma expansion within the first few hours after symptom onset. Early hematoma growth directly correlates with neurological deterioration, permanent disability, and 30-day mortality. Acute, extreme blood pressure elevation is the predominant modifiable driver of hematoma expansion.

Landmark Clinical Trials: INTERACT-2 and ATACH-2

The optimal blood pressure target in acute sICH was defined through two major international randomized controlled trials:

INTERACT-2 Trial (2013) : Randomly assigned 2,839 sICH patients presenting within 6 hours with SBP between 150 and 220 mmHg to intensive blood pressure lowering (target SBP < 140 mmHg <140\text{ mmHg} < 140 mmHg within 1 hour) versus standard guideline-based lowering (target SBP < 180 mmHg <180\text{ mmHg} < 180 mmHg ). The primary outcome (death or major disability) narrowly missed significance (OR 0.87, p=0.06), but the ordinal analysis showed a favorable shift in modified Rankin Scale scores at 90 days (OR 0.87, p=0.04) without increasing mortality or serious adverse events.

ATACH-2 Trial (2016) : Evaluated 1,000 sICH patients presenting within 4.5 hours randomized to intensive reduction (target SBP 110 to 139 mmHg ) versus standard reduction (target SBP 140 to 179 mmHg ) using intravenous nicardipine. The trial was halted prematurely for futility: the intensive group showed no significant reduction in death or severe disability at 90 days compared to the standard group. Crucially, the intensive arm experienced a significantly higher rate of renal adverse events within 7 days (9.0% vs. 4.0%, p=0.002) and an increased incidence of cardiac adverse events.

Contemporary Guideline Consensus (AHA/ASA 2022 Guidelines)

Target Blood Pressure : In mild-to-moderate ICH with SBP between 150 and 220 mmHg, acute lowering to a target SBP of 140 mmHg, maintained in the 130 to 150 mmHg range , is safe and may improve functional outcome (Class 2b). Start treatment within 2 hours of presentation and reach the target within about 1 hour.

The Lower Floor : Lowering SBP below 130 mmHg in these patients is potentially harmful (Class 3: Harm), consistent with ATACH-2's renal adverse events.

Large or Severe Hemorrhage : The benefit of intensive lowering is not established for large hematomas or patients needing surgical decompression.

Pharmacologic Selection : Continuous intravenous infusions of nicardipine (5 to 15 mg/h) or clevidipine (1 to 32 mg/h) are preferred over intermittent IV boluses. Continuous infusions minimize blood pressure variability; large systolic fluctuations are independently associated with hematoma expansion and poor neurologic recovery.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Pharmacotherapy

Aneurysmal subarachnoid hemorrhage, most commonly resulting from the rupture of an intracranial saccular "berry" aneurysm, presents with a sudden, catastrophic "thunderclap" headache. Medical management focuses on two distinct phases: preventing pre-securement aneurysm rebleeding, and preventing delayed cerebral ischemia (DCI).

1. Pre-Securement Blood Pressure Management

Prior to surgical clipping or endovascular coiling of the ruptured aneurysm, the unsecured vascular pouch is under extreme transmural stress. A sudden blood pressure surge can trigger fatal aneurysm rebleeding (which carries an 80% mortality rate). However, excessive hypotension reduces cerebral perfusion pressure, causing ischemic stroke.

Guideline Blood Pressure Target : Maintain SBP < 160 mmHg <160\text{ mmHg} < 160 mmHg (or mean arterial pressure [MAP] < 110 mmHg <110\text{ mmHg} < 110 mmHg ) using titratable IV infusions (nicardipine, clevidipine, or labetalol) prior to aneurysm securing.

Once the aneurysm is definitively secured by clipping or coiling, blood pressure targets are relaxed; induced permissive hypertension is utilized if delayed cerebral ischemia develops.

2. Neuroprotection & Vasospasm Prevention: Nimodipine

Delayed cerebral ischemia (DCI) typically develops between day 4 and day 14 post-bleed (peaking at days 7 to 10). Historically attributed solely to large-vessel macrovascular vasospasm visible on angiography, contemporary evidence demonstrates that DCI is primarily driven by microvascular spasm, microthrombosis, cortical spreading depolarization, and calcium-dependent apoptotic neuronal cell death.

Pharmacologic Agent of Choice : Nimodipine .

Mechanism : Highly lipophilic dihydropyridine calcium channel blocker that readily crosses the blood-brain barrier. Nimodipine does not significantly reverse or prevent macroscopic large-vessel vasospasm on catheter angiography; rather, it provides profound neuroprotection by preventing intracellular calcium overload in ischemic neurons and stabilizing microvascular tone.

Dosing & Duration : 60 mg orally (or via nasogastric/orogastric tube) every 4 hours for 21 consecutive days , initiated within 96 hours of symptom onset.

Warning

FATAL IF GIVEN INTRAVENOUSLY: The Nimodipine Black Box Warning Nimodipine must NEVER be administered intravenously . Accidental intravenous injection of the liquid contents of oral nimodipine capsules into central or peripheral venous lines has resulted in severe refractory hypotension, cardiovascular collapse, cardiac arrest, and death. If the patient cannot swallow capsules, the liquid must be extracted using a dedicated enteral/oral syringe (ENFit) that is physically incompatible with intravenous luer-lock lines and boldly labeled: "FOR ORAL / ENTERAL USE ONLY — FATAL IF GIVEN IV."

Managing Nimodipine-Induced Hypotension : If SBP drops below 90 to 100 mmHg during nimodipine therapy, do NOT permanently discontinue the drug. Instead, adjust the dosing interval to 30 mg orally every 2 hours , administer isotonic intravenous crystalloids to support intravascular volume, or co-administer a low-dose vasopressor (norepinephrine) to maintain perfusion while preserving the 21-day neuroprotective course.

Osmotherapy for Intracranial Hypertension & Cerebral Edema

Intracranial pressure (ICP) dynamics are governed by the Monro-Kellie Doctrine , which dictates that the rigid cranial vault has a fixed total volume occupied by three non-compressible components: brain parenchyma (80%), blood (10%), and cerebrospinal fluid (10%):

V i n t r a c r a n i a l = V b r a i n + V b l o o d + V C S F = Constant V_{intracranial} = V_{brain} + V_{blood} + V_{CSF} = \text{Constant} V in t r a cr ania l ​ = V b r ain ​ + V b l oo d ​ + V CSF ​ = Constant

When a mass lesion, hematoma, or severe cytotoxic/vasogenic edema expands one compartment, compensatory displacement of venous blood and CSF occurs. Once these spatial compensatory mechanisms are exhausted, intracranial pressure rises exponentially. Normal ICP is 5 to 15 mmHg ; sustained elevations > 20 to 22 mmHg >20\text{ to }22\text{ mmHg} > 20 to 22 mmHg require immediate emergency intervention to maintain Cerebral Perfusion Pressure (CPP):

C P P = M A P − I C P ( Clinical Goal: 60 to 70 mmHg ) CPP = MAP - ICP \quad (\text{Clinical Goal: } 60\text{ to }70\text{ mmHg}) CPP = M A P − I CP ( Clinical Goal: 60 to 70 mmHg )

Loading diagram...

1. Hypertonic Saline (HTS)

Hypertonic sodium chloride solutions create an osmotic gradient across an intact blood-brain barrier, drawing free water from the intracellular and interstitial compartments of brain tissue into the intravascular space, rapidly decreasing brain tissue volume and ICP.

3% Hypertonic Saline (Osmolarity: 1,026 mOsm/L; 513 mEq/L Na+) :

Dosing : 250 to 500 mL IV bolus administered over 15 to 30 minutes, or continuous infusion titrated to target serum sodium.

Laboratory Targets : Target serum sodium 145 to 155 mEq/L ; target serum osmolarity < 320 mOsm/L <320\text{ mOsm/L} < 320 mOsm/L .

Clinical Advantages : Preserves and expands intravascular volume, increases cardiac output, and supports blood pressure. Preferred osmotherapy in hypotensive neurotrauma or polytrauma patients .

Complications : Hyperchloremic metabolic acidosis (chloride load drives renal bicarbonate excretion), hypokalemia, and volume overload. If chronic hyponatremia is present, rapid sodium overcorrection can precipitate fatal osmotic demyelination syndrome (central pontine myelinolysis) .

23.4% Sodium Chloride ("Salt Bomb" / Super-Hypertonic Saline; Osmolarity: ~8,008 mOsm/L; 4 mEq/mL Na+) :

Dosing : 30 mL IV bolus administered over 10 to 15 minutes .

Clinical Indication : Emergent rescue therapy for impending cerebral herniation (unilateral blown pupil, decerebrate posturing, or Cushing's triad: hypertension, bradycardia, irregular breathing).

Vascular Access Mandate : Strictly requires a Central Venous Catheter (CVC) due to severe chemical thrombophlebitis and catastrophic skin necrosis if peripheral extravasation occurs (can be given through a large, dedicated proximal peripheral IV only in an extreme, cardiac-arrest-adjacent crisis while CVC is established).

2. 20% Mannitol

Mannitol is an impermeant hexahydroxy sugar alcohol that acts as an osmotic diuretic.

Dosing : 0.5 to 1 g/kg IV (20% solution provides 20 g / 100 mL; typical adult dose 50 to 100 g) administered over 20 to 30 minutes.

Dual Mechanism :

Rheologic Effect (Immediate, 1 to 5 min) : Decreases blood viscosity, expands intravascular volume, and causes reflex cerebral vasoconstriction while maintaining cerebral oxygen delivery.

Osmotic Effect (Delayed, 15 to 30 min) : Establishes a transmembrane osmotic gradient drawing water from the brain parenchyma into the vascular compartment for renal excretion.

Administration Requirement : Must be infused through an in-line filter (0.22 or 5 micron). Mannitol crystallizes readily at room temperature; crystallized vials must be inspected and warmed to redissolve crystals prior to infusion.

Complications & Contraindications :

Induces profound osmotic diuresis, leading to severe hypovolemia, hypotension, and prerenal azotemia.

Contraindications : Systolic blood pressure < 90 mmHg <90\text{ mmHg} < 90 mmHg or active shock, anuria, severe renal failure, and pulmonary edema/severe congestive heart failure (initial transient intravascular expansion exacerbates pulmonary capillary hydrostatic pressure).

Monitoring : Check serum osmolarity and osmolar gap every 6 to 8 hours. Withhold mannitol if the osmolar gap exceeds 15 to 20 mOsm/kg or serum osmolarity exceeds 320 mOsm/kg due to acute tubular necrosis risk.

Osmotherapy Comparison Matrix

Pharmacologic Agent Osmolarity & Content Standard ED Dosing Administration Route & Setup Key Advantages & Absolute Contraindications

3% Hypertonic Saline 1,026 mOsm/L (513 mEq/L Na+) 250 to 500 mL IV over 15–30 min Peripheral IV (large bore) or Central Line Expands intravascular volume; ideal in hypotension/shock. Risk of hyperchloremic acidosis.

23.4% Sodium Chloride ~8,008 mOsm/L (4 mEq/mL Na+) 30 mL IV bolus over 10–15 min Strictly Central Venous Line Emergency salvage for acute herniation crisis. Severe phlebitis/tissue necrosis if extravasated.

20% Mannitol 1,098 mOsm/L (0.2 g/mL) 0.5 to 1 g/kg IV over 20–30 min Peripheral or Central; In-line filter required Potent osmotic diuresis. Contraindicated in hypotension (SBP <90 mmHg) and anuria.